C
Chiara Silacci-Fregni
Researcher at University of Lugano
Publications - 24
Citations - 3152
Chiara Silacci-Fregni is an academic researcher from University of Lugano. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 12, co-authored 18 publications receiving 1334 citations. Previous affiliations of Chiara Silacci-Fregni include University of Washington & Rega Institute for Medical Research.
Papers
More filters
Journal ArticleDOI
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
Luca Piccoli,Young-Jun Park,M. Alejandra Tortorici,M. Alejandra Tortorici,Nadine Czudnochowski,Alexandra C. Walls,Martina Beltramello,Chiara Silacci-Fregni,Dora Pinto,Laura E. Rosen,John E. Bowen,Oliver J. Acton,Stefano Jaconi,Barbara Guarino,Andrea Minola,Fabrizia Zatta,Nicole Sprugasci,Jessica Bassi,Alessia Peter,Anna De Marco,Jay C. Nix,Federico Mele,Sandra Jovic,Blanca Fernandez Rodriguez,Sneha V. Gupta,Feng Jin,Giovanni Piumatti,Giovanni Piumatti,Giorgia Lo Presti,Alessandra Franzetti Pellanda,Maira Biggiogero,Maciej Tarkowski,Matteo Samuele Pizzuto,Elisabetta Cameroni,Colin Havenar-Daughton,Megan Smithey,David K. Hong,Valentino Lepori,Emiliano Albanese,Alessandro Ceschi,Alessandro Ceschi,Enos Bernasconi,Luigia Elzi,Paolo Ferrari,Christian Garzoni,Agostino Riva,G. Snell,Federica Sallusto,Katja Fink,Herbert W. Virgin,Antonio Lanzavecchia,Davide Corti,David Veesler +52 more
TL;DR: It is found that both the magnitude of Ab responses to SARS-CoV-2 spike (S) and nucleoprotein and nAb titers correlate with clinical scores, and the immunodominance of the receptor-binding motif will guide the design of COVID-19 vaccines and therapeutics.
Journal ArticleDOI
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Dami A. Collier,Dami A. Collier,Anna De Marco,Isabella Ferreira,Bo Meng,Rawlings Datir,Rawlings Datir,Alexandra C. Walls,Steven Kemp,Steven Kemp,Jessica Bassi,Dora Pinto,Chiara Silacci-Fregni,Siro Bianchi,M. Alejandra Tortorici,John E. Bowen,Katja Culap,Stefano Jaconi,Elisabetta Cameroni,Gyorgy Snell,Matteo Samuele Pizzuto,Alessandra Franzetti Pellanda,Christian Garzoni,Agostino Riva,Anne Elmer,Nathalie Kingston,Barbara J. Graves,Laura E. McCoy,Kenneth G. C. Smith,John Bradley,Nigel J. Temperton,Lourdes Ceron-Gutierrez,Gabriela Barcenas-Morales,William T. Harvey,Herbert W. Virgin,Antonio Lanzavecchia,Luca Piccoli,Rainer Doffinger,Mark R. Wills,David Veesler,Davide Corti,Ravindra K. Gupta +41 more
TL;DR: In this article, the authors assessed the immune responses of individuals after vaccination with the mRNA-based vaccine BNT162b22.1.7 and found that the emergence of the E484K substitution in a B.1, 1.1., 1.7 background represents a threat to the efficacy of the BNT 162b2 vaccine.
Journal ArticleDOI
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.
Matthew McCallum,Jessica Bassi,Anna De Marco,Alexander Chen,Alexandra C. Walls,Julia di Iulio,M. Alejandra Tortorici,Mary-Jane Navarro,Chiara Silacci-Fregni,Christian Saliba,Kaitlin R. Sprouse,Maria De Agostini,Dora Pinto,Katja Culap,Siro Bianchi,Stefano Jaconi,Elisabetta Cameroni,John E. Bowen,Sasha W Tilles,Matteo Samuele Pizzuto,Sonja Bernasconi Guastalla,Giovanni Bona,Alessandra Franzetti Pellanda,Christian Garzoni,Wesley C. Van Voorhis,Laura E. Rosen,Gyorgy Snell,Amalio Telenti,Herbert W. Virgin,Luca Piccoli,Davide Corti,David Veesler +31 more
TL;DR: In this paper, a novel variant of concern (VOC) named CAL.20C (B.1.427/B. 1.429), which was originally detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal domain (NTD), and L452R in the receptor-binding domain (RBD).
Journal ArticleDOI
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
Tyler N. Starr,Nadine Czudnochowski,Zhuoming Liu,Fabrizia Zatta,Young-Jun Park,Amin Addetia,Dora Pinto,Martina Beltramello,Patrick Hernandez,Allison J. Greaney,Allison J. Greaney,Roberta Marzi,William G. Glass,Ivy Zhang,Ivy Zhang,Adam S. Dingens,John E. Bowen,M. Alejandra Tortorici,Alexandra C. Walls,Jason A. Wojcechowskyj,Anna De Marco,Laura E. Rosen,Jiayi Zhou,Martin Montiel-Ruiz,Hannah Kaiser,Josh Dillen,Heather Tucker,Jessica Bassi,Chiara Silacci-Fregni,Michael P. Housley,Julia di Iulio,Gloria Lombardo,Maria L. Agostini,Nicole Sprugasci,Katja Culap,Stefano Jaconi,Marcel Meury,Exequiel Dellota,Rana Abdelnabi,Shi-Yan Caroline Foo,Elisabetta Cameroni,Spencer Stumpf,Tristan I. Croll,Jay C. Nix,Colin Havenar-Daughton,Luca Piccoli,Fabio Benigni,Johan Neyts,Amalio Telenti,Florian A. Lempp,Matteo Samuele Pizzuto,John D. Chodera,Christy M. Hebner,Herbert W. Virgin,Herbert W. Virgin,Sean P. J. Whelan,David Veesler,Davide Corti,Jesse D. Bloom,Jesse D. Bloom,Jesse D. Bloom,Gyorgy Snell +61 more
TL;DR: In this paper, the authors comprehensively characterize escape, breadth and potency across a panel of SARS-CoV-2 antibodies targeting the receptor-binding domain (RBD).
Journal ArticleDOI
Broad betacoronavirus neutralization by a stem helix-specific human antibody.
Dora Pinto,Dora Pinto,Maximilian M. Sauer,Nadine Czudnochowski,Jun Siong Low,Jun Siong Low,M. Alejandra Tortorici,Michael P. Housley,Julia Noack,Alexandra C. Walls,John E. Bowen,Barbara Guarino,Barbara Guarino,Laura E. Rosen,Julia di Iulio,Josipa Jerak,Josipa Jerak,Josipa Jerak,Hannah Kaiser,Saiful Islam,Stefano Jaconi,Stefano Jaconi,Nicole Sprugasci,Nicole Sprugasci,Katja Culap,Katja Culap,Rana Abdelnabi,Caroline S. Foo,Lotte Coelmont,Istvan Bartha,Istvan Bartha,Siro Bianchi,Siro Bianchi,Chiara Silacci-Fregni,Chiara Silacci-Fregni,Jessica Bassi,Roberta Marzi,Roberta Marzi,Eneida Vetti,Eneida Vetti,Antonino Cassotta,Antonino Cassotta,Alessandro Ceschi,Paolo Ferrari,Pietro E. Cippà,Olivier Giannini,Samuele Ceruti,Christian Garzoni,Agostino Riva,Fabio Benigni,Fabio Benigni,Elisabetta Cameroni,Elisabetta Cameroni,Luca Piccoli,Luca Piccoli,Matteo Samuele Pizzuto,Matteo Samuele Pizzuto,Megan Smithey,David I. Hong,Amalio Telenti,Florian A. Lempp,Johan Neyts,Colin Havenar-Daughton,Antonio Lanzavecchia,Antonio Lanzavecchia,Federica Sallusto,Federica Sallusto,Gyorgy Snell,Herbert W. Virgin,Martina Beltramello,Davide Corti,David Veesler +71 more
TL;DR: In this article, the authors describe five monoclonal antibodies cross-reacting with the stem helix of multiple β-coronavirus spike glycoproteins isolated from COVID-19 convalescent individuals.